145 related articles for article (PubMed ID: 2772867)
1. Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin.
Doutremepuich C; Deharo E; Guyot M; Lalanne MC; Walenga J; Fareed J
Thromb Res; 1989 Jun; 54(5):435-45. PubMed ID: 2772867
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model.
Doutremepuich C; Lalanne MC; Doutremepuich F; Walenga J; Fareed J; Breddin HK
Haemostasis; 1991; 21 Suppl 1():99-106. PubMed ID: 1894201
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic action of recombinant hirudin in a venous thrombosis model.
Raake W; Klauser RJ; Elling H; Zeiller P
Haemostasis; 1991; 21 Suppl 1():127-32. PubMed ID: 1654293
[TBL] [Abstract][Full Text] [Related]
4. Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model.
Krupinski K; Breddin HK
Haemostasis; 1991; 21 Suppl 1():88-92. PubMed ID: 1894199
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
Zhang B; Wieslander JB
Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
[TBL] [Abstract][Full Text] [Related]
6. Studies on antithrombotic effects of recombinant hirudin.
Markwardt F; Kaiser B; Nowak G
Thromb Res; 1989 Jun; 54(5):377-88. PubMed ID: 2772864
[TBL] [Abstract][Full Text] [Related]
7. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
8. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
9. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
[TBL] [Abstract][Full Text] [Related]
10. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
11. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.
Freund M; Cazenave JP; Courtney M; Degryse E; Roitsch C; Bernat A; Delebassée D; Defreyn G; Maffrand JP
Thromb Haemost; 1990 Apr; 63(2):187-92. PubMed ID: 2363120
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic effects of recombinant hirudin in different animal models.
Just M; Tripier D; Seiffge D
Haemostasis; 1991; 21 Suppl 1():80-7. PubMed ID: 1716605
[TBL] [Abstract][Full Text] [Related]
13. Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis model.
Fu K; Izquierdo R; Walenga JM; Fareed J
Thromb Res; 1995 Jun; 78(5):421-8. PubMed ID: 7660358
[TBL] [Abstract][Full Text] [Related]
14. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
15. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
Topol EJ; Fuster V; Harrington RA; Califf RM; Kleiman NS; Kereiakes DJ; Cohen M; Chapekis A; Gold HK; Tannenbaum MA
Circulation; 1994 Apr; 89(4):1557-66. PubMed ID: 8149521
[TBL] [Abstract][Full Text] [Related]
16. [Subcutaneous recombinant hirudin in the treatment of deep venous thrombosis. A pharmacokinetic study].
Schiele F; Vuillemenot A; Mouhat T; Kramarz P; Kieffer Y; Camez A; Bassand JP
Arch Mal Coeur Vaiss; 1995 Mar; 88(3):329-35. PubMed ID: 7487286
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
[TBL] [Abstract][Full Text] [Related]
18. Comparative study on the antithrombotic efficacy of hirudin, heparin and a low-molecular weight heparin in preventing experimentally induced venous thrombosis.
Monreal M; Galego G; Monreal L; Angles AM; Monasterio J; Oller B
Haemostasis; 1993; 23(3):179-83. PubMed ID: 8276322
[TBL] [Abstract][Full Text] [Related]
19. Hirudin: clinical potential of a thrombin inhibitor.
Johnson PH
Annu Rev Med; 1994; 45():165-77. PubMed ID: 8198374
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor.
Arnljots B; Bergqvist D
Plast Reconstr Surg; 1995 Apr; 95(5):894-900. PubMed ID: 7708874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
